IBRX
Immunitybio Inc
NASDAQ: IBRX · HEALTHCARE · BIOTECHNOLOGY
$6.96
+0.00% today
Updated 2026-04-29
Market cap
$7.19B
P/E ratio
—
P/S ratio
63.45x
EPS (TTM)
$-0.38
Dividend yield
—
52W range
$2 – $12
Volume
27.9M
Immunitybio Inc (IBRX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $600000.00 | $641000.00 | $236000.00 | $44000.00 | $45000.00 | $47000.00 | $43000.00 | $605000.00 | $934000.00 | $240000.00 | $622000.00 | $14.74M | $113.29M |
| Revenue growth (YoY) | — | +6.8% | -63.2% | -81.4% | +2.3% | +4.4% | -8.5% | +1307.0% | +54.4% | -74.3% | +159.2% | +2270.6% | +668.3% |
| Cost of revenue | $253000.00 | $323000.00 | — | — | — | $-3.11M | $9.01M | $9.15M | — | $24.19M | $18.51M | $17.55M | $753000.00 |
| Gross profit | $347000.00 | $641000.00 | $236000.00 | $44000.00 | $45000.00 | $3.16M | $-8.97M | $605000.00 | $934000.00 | $240000.00 | $622000.00 | $14.74M | $112.53M |
| Gross margin | 57.8% | 100.0% | 100.0% | 100.0% | 100.0% | 6717.0% | -20858.1% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 99.3% |
| R&D | $446000.00 | $1.59M | $11.43M | $26.55M | $39.78M | $53.42M | $48.88M | $139.51M | $195.96M | $248.15M | $232.37M | $190.14M | $207.88M |
| SG&A | — | $4.33M | $227.68M | $95.39M | $57.12M | $28.39M | $18.07M | $27.25M | $135.26M | $102.71M | $122.72M | $168.78M | $150.00M |
| Operating income | $-2.27M | $-6.21M | $-238.88M | $-124.50M | $-99.12M | $-98.39M | $-66.91M | $-220.88M | $-330.28M | $-351.30M | $-362.25M | $-344.18M | $-256.03M |
| Operating margin | -378.2% | -969.1% | -101218.6% | -282954.5% | -220266.7% | -209338.3% | -155597.7% | -36509.1% | -35361.9% | -146374.2% | -58239.5% | -2334.2% | -226.0% |
| EBITDA | $-1.58M | $-5.68M | $-235.71M | $-117.71M | $-90.73M | $-86.74M | $-56.85M | $-204.22M | $-320.75M | $-351.88M | $-478.66M | $-264.43M | $-223.56M |
| EBITDA margin | -263.2% | -885.6% | -99875.0% | -267518.2% | -201626.7% | -184555.3% | -132220.9% | -33755.4% | -34341.8% | -146617.1% | -76955.5% | -1793.4% | -197.3% |
| EBIT | $-1.58M | $-5.80M | $-237.18M | $-121.31M | $-96.30M | $-96.30M | $-65.87M | $-216.96M | $-334.99M | $-370.14M | $-497.18M | $-281.99M | $-239.08M |
| Interest expense | $463000.00 | $0.00 | $0.00 | $66000.00 | $618000.00 | $433000.00 | $5.92M | $9.07M | $14.85M | $47.15M | $86.72M | $131.66M | $112.53M |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-2.05M | $-6.21M | $-236.88M | $-120.81M | $-96.42M | $-96.23M | $-65.79M | $-221.85M | $-346.79M | $-416.57M | $-583.20M | $-413.56M | $-351.40M |
| Net income growth (YoY) | — | -203.5% | -3712.6% | +49.0% | +20.2% | +0.2% | +31.6% | -237.2% | -56.3% | -20.1% | -40.0% | +29.1% | +15.0% |
| Profit margin | -341.2% | -969.3% | -100371.2% | -274565.9% | -214273.3% | -204736.2% | -152997.7% | -36669.6% | -37129.6% | -173569.6% | -93761.4% | -2804.8% | -310.2% |